The major classification of BC is generally based on the expression of ERα, progesterone receptor (PR) or over-expression and/or amplification of the human epidermal growth factor receptor 2 (HER2/neu); their presence is assessed to predict prognosis as well as the potential response to endocrine treatments [38,39]. This evidence concerns the gene ESR1 and breast cancer.